Genor Biopharma files new listing application for reverse takeover

Genor Biopharma Holdings Limited (HKEX:6998) announced the filing of its new listing application with the Stock Exchange on April 15, 2025, as part of a very substantial acquisition and proposed merger involving a reverse takeover. This filing follows the initial announcement on October 7, 2024, and includes applications for a whitewash waiver, special deals for shareholder personnel retention, a company name change, an increase in authorised share capital, and a one-off share option plan. Shareholders and potential investors are cautioned that the merger's completion is subject to conditions precedent and the approval of the new listing application. Despatch of the Circular has been extended to on or before June 30 2025. The company has provided a warning that the merger and related agreements are contingent on regulatory and shareholder approvals.